Japan Approves New Canalia Dosage
Mitsubishi Tanabe Pharma Corporation, a member of the Mitsubishi Chemical Group, obtained approval for an additional dosage form of Canalia Combination OD Tablets, which is orally disintegrating tablets (OD tablets), the combination drug of selective DPP-4 inhibitor and SGLT2 inhibitor
Canalia Combination OD Tablets is the first OD tablets of selective DPP-4 inhibitor and SGLT2 inhibitor combination drug approved in Japan. Since it disintegrates easily in a small amount of water, it dissolves quickly with saliva in the mouth and is easy to swallow and can be taken without or with water without depending on the place. It is expected to improve convenience and to continue taking the drug for people with type 2 diabetes who need continuous treatment.
Use of Canalia Combination OD Tablets by patients with type 2 diabetes mellitus whose blood glucose levels are stably controlled by concomitant treatment with selective DPP-4 inhibitor Tenelia Tablets/ OD Tablets and SGLT2 inhibitor Canaglu Tablets/OD Tablets will reduce the number of medicines and improve medication adherence. Use of Canalia Combination OD Tablets by type 2 diabetes mellitus patients who have inadequate glycemic control to monotherapy with Tenelia or Canaglu also expected to result in improved blood glucose control.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins